References
- Pelechas E, Voulgari PV, Drosos AA. Sirukumab: a promising therapy for rheumatoid arthritis. Expert Opin Biol Ther. 2017;17(6):755–763.
- Zikou AK, Argyropoulou MI, Voulgari PV, et al. Magnetic resonance imaging quantification of hand synovitis in patients with rheumatoid arthritis treated with adalimumab. J Rheumatol. 2006;33(2):219–223.
- Smolen SJ, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023–2038. published online May 3.
- Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part I. Arthritis Rheum. 2008;58:15–25.
- Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum. 2006;36:182–188.
- Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev. 2005;4:130–136.
- Brooks PM. The burden of musculoskeletal disease – a global perspective. Clin Rheumatol. 2006;25(6):778–781.
- Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2016;68(1):1–25.
- Pincus T. RAPID3, an index of only 3 patient self-report core data set measures, but not ESR, recognizes incomplete responses to methotrexate in usual care of patients with rheumatoid arthritis. Bull Hosp Jt Dis. 2013;71(2):117–120.
- Moreland LW, O’Dell JR, Paulus HE, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of early aggressive rheumatoid arthritis trial. Arthritis Rheum. 2012;64(9):2824–2835.
- Papadopoulos NG, Alamanos Y, Papadopoulos IA, et al. Disease modifying antirheumatic drugs in early rheumatoid arthritis: a long-term observational study. J Rheumatol. 2002;29(2):261–266.
- Rosales Rosado Z, Leon L, Freites Nunez D, et al. Survival of disease-modifying antirheumatic drugs in rheumatoid arthritis [abstract]. Arthritis Rheumatol. 2016;68(suppl10). cited 2017 Sep 11. Available from: http://acrabstracts.org/abstract/survival-of-disease-modifying-antirheumatic-drugs-in-rheumatoid-arthritis/
- Pelechas E. JAK inhibitors: a promising direction for treating rheumatoid arthritis. Int J Pharm Sci Dev Res. 2017;3(1):29.
- Humira Lifts AbbVie 2.8% in Q2. Discovery and development. Rockaway, New Jersey, United States: Associated Press; 2014 July 25. cited 2017 Sep 23. Available from: https://www.dddmag.com/news/2014/07/humira-lifts-abbvie-28-q2
- Voulgari PV, Drosos AA. Adalimumab for rheumatoid arthritis. Expert Opin Biol Ther. 2006;6(12):1349–1360.
- Bang LM, Keating GM. Adalimumab: a review of its use in rheumatoid arthritis. BioDrugs. 2004;18(2):121–139.
- Santora LC, Krull IS, Grant K. Characterization of recombinant human monoclonal tissue necrosis factor-alpha antibody using cation-exchange HPLC and capillary isoelectric focusing. Anal Biochem. 1999;275(1):98–108.
- Adalimumab EMA. Summary of product characteristics. Committee for medicinal products for human use (CHMP). EMA/CHMP/487292/2012 cited 2017 Sep 23. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000481/WC500130118.pdf.
- Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117:244–279.
- Kobelt G, Kasteng F Access to innovative treatments in rheumatoid arthritis in Europe. European Federation of Pharmaceutical Industry Associations (EFPIA);2009. cited 2017 Sep 23. Available from: http://www.comparatorreports.se/Access%20to%20RA%20Treatments%20October%202009.pdf.
- Taylor PC, Moore A, Vasilescu R, et al. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int. 2016;36(5):685–695.
- Dorner T, Strand V, Cornes P, et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis. 2016;1–9. DOI:10.1136/annrheumdis-2016-209166.
- Kay J, Schoels MM, Dorner T, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2017:1–10. DOI:10.1136/annrheumdis-2017-211937.
- Awni VM, Cascella P, Oleka N, et al. Steady-state pharmacokinetics of adalimumab (Humira™) following 40 mg subcutaneous infection every other week in rheumatoid arthritis patients with and without methotrexate background therapy (abstract). Arthritis Rheum. 2003;48(Suppl):S141.
- Den Broeder A, van de Putte L, Rau R, et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol. 2002;29(11):2288–2298.
- Liu J, Eris T, Li C, et al. Assessing analytical similarity of proposed amgen biosimilar ABP 501 to adalimumab. BioDrugs. 2016;30:321–338.
- Velayudhan J, Chen YF, Rohrbach A, et al. demonstration of functional similarity of proposed biosimilar ABP 501 to Adalimumab. BioDrugs. 2016;30:339–351.
- Kaur P, Chow V, Zhang N, et al. A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab. Ann Rheum Dis. 2017;76:526–533.
- Prescribing information leaflet for AMJEVITA (adalimumab-atto). Initial U.S. Approval: 2016. cited 2017 Sep 25. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761024lbl.pdf.
- European Medicines Agency. Guideline on similar biological medicinal products. cited 2017 Sep 25. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf.
- US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product. Guidance for industry. cited 2017 Sep 25. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291134.pdf.
- Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety trial of adalimumab in rheumatoid arthritis). J Rheumatol. 2003;30(12):2563–2571.
- Van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004;63(5):508–516.
- Winblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48(1):35–45.
- Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50(5):1400–1411.
- Voulgari PV, Kaltsonoudis E, Papagoras C, et al. Adalimumab in the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2012;12(12):1679–1686.
- Cohen S, Genovese M, Choy E, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis. Published Online First: 05 June 2017. DOI:10.1136/annrheumdis-2016-210459.
- AMGEN Inc. Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA) in Adults With Moderate to Severe Plaque Psoriasis. cited 2017 Sep 26. ClinicalTrials.gov identifier: NCT01970488. Available from: https://clinicaltrials.gov/ct2/show/NCT01970488.
- AMGEN Inc. Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis (RA). cited 2017 Sep 26. ClinicalTrials.gov identifier: NCT01970475. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01970475.
- AMGEN Inc. Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis. cited 2017 Sep 27. ClinicalTrials.gov identifier: NCT02114931. Available from: http://clinicaltrials.gov/ct2/show/NCT02114931.
- Cohen S, Pablos JL, Zhang N, et al. ABP 501 long-term safety/efficacy: interim results from an open-label extension study [abstract]. Arthritis Rheumatol. 2016;68(suppl 10). cited 2017 Sep 27. Available from: http://acrabstracts.org/abstract/abp-501-long-term-safetyefficacy-interim-results-from-an-open-label-extension-study/.
- US Department of Health and Human Services, Food and Drug Administration, Center For Drug Evaluation and Research. cited 2017 Sep 26. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761024Orig1s000Approv.pdf.
- Kuek A, Hazleman BL, Ostor AJK. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J. 2007;83:251–260.
- Owens GM. The value of biologics. Am Health Drug Benefits. 2008;1(2):20–28.
- Blackstone EA, Joseph PF. The economics of biosimilars. Am Health Drug Benefits. 2013;6(8):469–478.
- European Medicines Agency. Amgevita – adalimumab. cited 2017 Sep 29. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004212/human_med_002081.jsp
- Papagoras C, Voulgari PV, Drosos AA. Long-term use of adalimumab in the treatment of rheumatic diseases. Open Access Rheumatol Res Rev. 2009;1:51–68.